Company Information

Get to know Aevitas Capital

Aevitas Capital is a specialized venture capital firm focused on advancing human health by investing in innovative life sciences and biotechnology companies. Founded by a team of pioneering gene therapy scientist-entrepreneurs and seasoned investors, the firm leverages its deep scientific and operational expertise to support its portfolio companies. Aevitas employs a data-driven and evidence-based investment approach, aiming to build and scale companies with the potential to deliver transformative therapies for patients with genetic diseases.

Industry

Financial FundraisingPRIMARY
Financial Other Service

Contact

Social

Company hasn't updated its information.

THIS SERVICE IS NOT AVAILABLE IN YOUR REGION

Aevitas Capital

India

Founded in

2020 (6 Years)

Founded

Last online: No recent activity

Claim company Visit website

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

OVERALL SCORE

Others

--/10

Reviews

--/90

0 reviews

Provided by TrustFinance

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.

Regulated

Recommended

IUX

(2,284 reviews)

Mauritius

2015

(10 years)

Security Information :

FSCA

FSC

ASIC

Security Information

Warning

This company is currently Unproved.

Please be cautious of the potential risks!

License

A Grade License

Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.

B Grade License

Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.

C Grade License

Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.

D Grade License

From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.